高级检索
当前位置: 首页 > 详情页

Systemic Administration of Fibroblast Growth Factor 21 Improves the Recovery of Spinal Cord Injury (SCI) in Rats and Attenuates SCI-Induced Autophagy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China [2]Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China [3]Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia [4]Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China [5]Kunming Tongren Hosp, Spinal Cord Injury Treatment Ctr, Kunming, Yunnan, Peoples R China [6]Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA
出处:
ISSN:

关键词: spinal cord injury fibroblast growth factor 21 autophagy nerve regeneration fibrotic scar

摘要:
Protecting the death of nerve cells is an essential tactic for spinal cord injury (SCI) repair. Recent studies show that nerve growth factors can reduce the death of nerve cells and promote the healing of nerve injury. To investigate the conducive effect of fibroblast growth factor 21 (FGF21) on SCI repair. FGF21 proteins were systemically delivered into rat model of SCI via tail vein injection. We found that administration of FGF21 significantly promoted the functional recovery of SCI as assessed by BBB scale and inclined plane test, and attenuated cell death in the injured area by histopathological examination with Nissl staining. This was accompanied with increased expression of NeuN, GAP43 and NF200, and deceased expression of GFAP. Interestingly, FGF21 was found to attenuate the elevated expression level of the autophagy marker LC3-II (microtubules associated protein 1 light chain 3-II) induced by SCI in a dose-dependent manner. These data show that FGF21 promotes the functional recovery of SCI via restraining injury-induced cell autophagy, suggesting that systemic administration of FGF21 could have a therapeutic potential for SCI repair.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2019]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China [2]Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China [3]Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia [4]Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China [2]Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China [3]Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia [4]Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China [6]Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)